doi: 10.3389/fcvm.2026.1708109 Received 18 September 2025 Revised 16 January 2026 Accepted 19 January 2026 Published 05 March 2026 Volume 13 - 2026 Edited by Rui Providencia, University College London, United Kingdom Reviewed by Marinela Couselo Seijas, Spanish National Centre for Cardiovascular Research, Spain Toluwalase Awoyemi, University of Oxford, United Kingdom Updates Copyright 2026 Liu and Lu
This Some by mi galactomyces glutathione glow serum mask tackles multiple concerns at once
Keeping momentum, CPG vet Tracey Warner Halama will step into the CEO role, replacing founder Marc Washington, who will move to executive chairman
Azzam AY, Essibayi MA, Farkas N et al (2024) Efficacy of Tirzepatide dual GIP/GLP-1 receptor agonist in patients with idiopathic intracranial hypertension
Individuals under 18 , pregnant , or breastfeeding
Semaglutide, on the other hand, lowered death from cardiovascular causes by 26% when compared with placebo